Pharsight

1. List of Abilify Mycite Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8847766	OTSUKA	Pharma-informatics system	Mar, 2030 (7 years from now)
US8545402	OTSUKA	Highly reliable ingestible event markers and methods for using the same	Apr, 2030 (7 years from now)
US8114021	OTSUKA	Body-associated receiver and method	Jun, 2030 (7 years from now)
US11464423	OTSUKA	In-body power source having high surface area electrode	Sep, 2030 (7 years from now)
US9941931	OTSUKA	System for supply chain management	Nov, 2030 (7 years from now)
US8961412	OTSUKA	In-body device with virtual dipole signal amplification	Nov, 2030 (7 years from now)
US8258962	OTSUKA	Multi-mode communication ingestible event markers and systems, and methods of using the same	Nov, 2030 (7 years from now)
US8547248	OTSUKA	Implantable zero-wire communications system	Dec, 2030 (7 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: Method of using a tablet embedded with a sensor that communicates information via a signal through the body of a patient to a receiver

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
15MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription

2. List of Acetaminophen drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741959	FRESENIUS KABI USA	Paracetamol for parenteral administration	Apr, 2030 (7 years from now)

Drugs and Companies using ACETAMINOPHEN ingredient

Market Authorisation Date: 28 October, 2015

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
1GM/100ML (10MG/ML)	SOLUTION;INTRAVENOUS	Prescription

3. List of Acuvue Theravision With Ketotifen drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9962376	JOHNSON JOHNSON VISN	Methods and ophthalmic devices used in the treatment of ocular allergies	Jun, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Feb 25, 2025

Drugs and Companies using KETOTIFEN FUMARATE ingredient

Market Authorisation Date: 25 February, 2022

Treatment: NA

Dosage: DRUG-ELUTING CONTACT LENS ;OPHTHALMIC

Strength	Dosage	Availability
EQ 19MCG BASE	DRUG-ELUTING CONTACT LENS ;OPHTHALMIC	Prescription

4. List of Akynzeo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623826	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Nov, 2030 (7 years from now)
US9943515	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Nov, 2030 (7 years from now)
US8951969	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Nov, 2030 (7 years from now)
US9186357	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Nov, 2030 (7 years from now)
US10828297	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Dec, 2030 (7 years from now)

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

Market Authorisation Date: 10 October, 2014

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
300MG;EQ 0.5MG BASE	CAPSULE;ORAL	Prescription

5. List of Akynzeo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186357	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Nov, 2030 (7 years from now)
US10828297	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Dec, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 19, 2023

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: April, 2022

Market Authorisation Date: 19 April, 2018

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
235 mg/0.25 mg per 20 mL	19 Apr, 2022	1		02 Jun, 2037

Strength	Dosage	Availability
EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription
EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription

6. List of Alecensa drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9440922	HOFFMANN-LA ROCHE	Tetracyclic compound	Jun, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Nov 6, 2024

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 11 December, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
150 mg	11 Dec, 2019	1		04 Mar, 2032

Strength	Dosage	Availability
EQ 150MG BASE	CAPSULE;ORAL	Prescription

7. List of Amondys 45 drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9228187	SAREPTA THERAPS INC	Antisense molecules and methods for treating pathologies	Nov, 2030 (7 years from now)
US10287586	SAREPTA THERAPS INC	Antisense molecules and methods for treating pathologies	Nov, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10781450	SAREPTA THERAPS INC	Antisense molecules and methods for treating pathologies	Nov, 2030 (7 years from now)
US9758783	SAREPTA THERAPS INC	Antisense molecules and methods for treating pathologies	Nov, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Feb 25, 2028
New Chemical Entity Exclusivity (NCE)	Feb 25, 2026

Drugs and Companies using CASIMERSEN ingredient

NCE-1 date: February, 2025

Market Authorisation Date: 25 February, 2021

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein production; Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
100MG/2ML (50MG/ML)	SOLUTION;INTRAVENOUS	Prescription

8. List of Amzeeq drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8945516	JOURNEY	Surfactant-free water-free foamable compositions, breakable foams and gels and their uses	Oct, 2030 (7 years from now)
US10265404	JOURNEY	Compositions, gels and foams with rheology modulators and uses thereof	Oct, 2030 (7 years from now)
US10821187	JOURNEY	Compositions, gels and foams with rheology modulators and uses thereof	Oct, 2030 (7 years from now)
US10517882	JOURNEY	Method for healing of an infected acne lesion without scarring	Oct, 2030 (7 years from now)
US10213512	JOURNEY	Topical tetracycline compositions	Oct, 2030 (7 years from now)
US10086080	JOURNEY	Topical tetracycline compositions	Oct, 2030 (7 years from now)
US8992896	JOURNEY	Topical tetracycline compositions	Oct, 2030 (7 years from now)
US10137200	JOURNEY	Surfactant-free water-free foamable compositions, breakable foams and gels and their uses	Oct, 2030 (7 years from now)
US9675700	JOURNEY	Topical tetracycline compositions	Oct, 2030 (7 years from now)
US8865139	JOURNEY	Topical tetracycline compositions	Oct, 2030 (7 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 October, 2019

Treatment: Treatment of non-nodular acne vulgaris

Dosage: AEROSOL, FOAM;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.04	11 May, 2021	1		08 Sep, 2037

Strength	Dosage	Availability
EQ 4% BASE	AEROSOL, FOAM;TOPICAL	Prescription

9. List of Anjeso drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11253478	BAUDAX	Reduction of flake-like aggregation in nanoparticulate active agent compositions	May, 2030 (7 years from now)
US9974746	BAUDAX	Reduction of flake-like aggregation in nanoparticulate active agent compositions	May, 2030 (7 years from now)
US10709713	BAUDAX	Nanoparticulate meloxicam formulations	May, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Feb 20, 2023

Drugs and Companies using MELOXICAM ingredient

Market Authorisation Date: 20 February, 2020

Treatment: Management of moderate-to-severe pain by injection; Management of moderate-to-severe pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
30MG/ML (30MG/ML)	SOLUTION;INTRAVENOUS	Prescription

10. List of Anoro Ellipta drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281	GLAXOSMITHKLINE	Manifold for use in medicament dispenser	Mar, 2030 (7 years from now)
US8746242	GLAXOSMITHKLINE	Medicament dispenser	Oct, 2030 (7 years from now)
US9750726	GLAXOSMITHKLINE	Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist	Nov, 2030 (7 years from now)
US11090294	GLAXOSMITHKLINE	Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist	Nov, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
M	Jun 9, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 18 December, 2013

Treatment: Maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription

11. List of Apadaz drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9132125	KVK TECH INC	Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof	Jul, 2030 (7 years from now)
US9549923	KVK TECH INC	Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof	Jul, 2030 (7 years from now)
US8748413	KVK TECH INC	Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof	Jul, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8828978	KVK TECH INC	Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof	Jul, 2030 (7 years from now)

Drugs and Companies using ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 February, 2018

Treatment: Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate

Dosage: TABLET;ORAL

Strength	Dosage	Availability
325MG;EQ 4.08MG BASE	TABLET;ORAL	Prescription
325MG;EQ 6.12MG BASE	TABLET;ORAL	Prescription
325MG;EQ 8.16MG BASE	TABLET;ORAL	Prescription

12. List of Apriso drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8865688	VALEANT PHARMS INTL	Compositions and methods for treatment of bowel diseases with granulated mesalamine	May, 2030 (7 years from now)

Drugs and Companies using MESALAMINE ingredient

Market Authorisation Date: 31 October, 2008

Treatment: For the maintenance of remission of ulcerative colitis

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.375 g	03 Apr, 2012	1		20 Apr, 2018	Extinguished

Strength	Dosage	Availability
375MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

13. List of Aptiom drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8372431	SUNOVION PHARMS INC	Pharmaceutical composition comprising licarbazepine acetate	Apr, 2030 (7 years from now)

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

Market Authorisation Date: 08 November, 2013

Treatment: NA

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
200 mg, 400 mg, 600 mg and 800 mg	08 Nov, 2017	7	29 Jun, 2021	24 Aug, 2032	Deferred

Strength	Dosage	Availability
200MG	TABLET;ORAL	Prescription
400MG	TABLET;ORAL	Prescription
600MG	TABLET;ORAL	Prescription
800MG	TABLET;ORAL	Prescription

14. List of Aristada drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112903	ALKERMES INC	Heterocyclic compounds for the treatment of neurological and psychological disorders	Jun, 2030 (7 years from now)
US8431576	ALKERMES INC	Heterocyclic compounds for the treatment of neurological and psychological disorders	Oct, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796276	ALKERMES INC	Heterocyclic compounds for the treatment of neurological and psychological disorders	Jun, 2030 (7 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Dosage	Availability
441MG/1.6ML (275.63MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
662MG/2.4ML (275.83MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
882MG/3.2ML (275.63MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
1064MG/3.9ML (272.82MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

15. List of Aristada Initio Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112903	ALKERMES INC	Heterocyclic compounds for the treatment of neurological and psychological disorders	Jun, 2030 (7 years from now)
US8431576	ALKERMES INC	Heterocyclic compounds for the treatment of neurological and psychological disorders	Oct, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796276	ALKERMES INC	Heterocyclic compounds for the treatment of neurological and psychological disorders	Jun, 2030 (7 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 29 June, 2018

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Dosage	Availability
675MG/2.4ML	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

16. List of Arnuity Ellipta drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281	GLAXOSMITHKLINE	Manifold for use in medicament dispenser	Mar, 2030 (7 years from now)
US8746242	GLAXOSMITHKLINE	Medicament dispenser	Oct, 2030 (7 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 20 August, 2014

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.05MG/INH	POWDER;INHALATION	Prescription
0.1MG/INH	POWDER;INHALATION	Prescription
0.2MG/INH	POWDER;INHALATION	Prescription

17. List of Atrovent Hfa drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8474447	BOEHRINGER INGELHEIM	Inhaler device	Jan, 2030 (6 years from now)

Drugs and Companies using IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 27 November, 2004

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

Strength	Dosage	Availability
0.021MG/INH	AEROSOL, METERED;INHALATION	Prescription

18. List of Aubagio drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802735	SANOFI AVENTIS US	(Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability	Sep, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
M	Apr 30, 2024
Pediatric Exclusivity (PED)	Oct 30, 2024

Drugs and Companies using TERIFLUNOMIDE ingredient

Market Authorisation Date: 12 September, 2012

Treatment: NA

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
7 mg and 14 mg	12 Sep, 2016	21	27 Jul, 2018	04 Feb, 2034	Eligible

Strength	Dosage	Availability
7MG	TABLET;ORAL	Prescription
14MG	TABLET;ORAL	Prescription

19. List of Auryxia drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9387191	KERYX BIOPHARMS	Ferric citrate dosage forms	Jul, 2030 (7 years from now)
US10300039	KERYX BIOPHARMS	Ferric citrate dosage forms	Jul, 2030 (7 years from now)

Drugs and Companies using FERRIC CITRATE ingredient

Market Authorisation Date: 05 September, 2014

Treatment: Control of serum phosphorus levels

Dosage: TABLET;ORAL

20. List of Avycaz drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835455	ALLERGAN	Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt	Oct, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 25, 2020
Generating Antibiotic Incentives Now (GAIN)	Feb 25, 2025

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 25 February, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS

21. List of Besivance drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8604020	BAUSCH AND LOMB	Fluoroquinolone carboxylic acid molecular crystals	Mar, 2030 (7 years from now)
US8415342	BAUSCH AND LOMB	Besifloxacin ophthalmic composition for the treatment or control of infection	Nov, 2030 (7 years from now)

Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient

Market Authorisation Date: 28 May, 2009

Treatment: Method of treating ocular bacterial infections

Dosage: SUSPENSION/DROPS;OPHTHALMIC

22. List of Bevespi Aerosphere drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324266	ASTRAZENECA	Compositions, methods and systems for respiratory delivery of two or more active agents	May, 2030 (7 years from now)
US10716753	ASTRAZENECA	Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems	May, 2030 (7 years from now)
US9415009	ASTRAZENECA	Compositions, methods and systems for respiratory delivery of two or more active agents	May, 2030 (7 years from now)
US8703806	ASTRAZENECA	Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents	May, 2030 (7 years from now)
US8808713	ASTRAZENECA	Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems	May, 2030 (7 years from now)
US9463161	ASTRAZENECA	Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems	May, 2030 (7 years from now)

Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

23. List of Bevyxxa drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8987463	PORTOLA PHARMS INC	Methods of synthesizing factor Xa inhibitors	Dec, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 23, 2022

Drugs and Companies using BETRIXABAN ingredient

NCE-1 date: June, 2021

Market Authorisation Date: 23 June, 2017

Treatment: NA

Dosage: CAPSULE;ORAL

24. List of Beyaz drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617597	BAYER HLTHCARE	Pharmaceutical composition containing a tetrahydrofolic acid	Feb, 2030 (7 years from now)

Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient

Market Authorisation Date: 24 September, 2010

Treatment: NA

Dosage: TABLET;ORAL

25. List of Braftovi drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8541575	ARRAY BIOPHARMA INC	3,4-diarylpyrazoles as protein kinase inhibitors	Feb, 2030 (7 years from now)
US9593099	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9850229	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US9593100	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US9850230	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US10005761	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 27, 2023
Orphan Drug Exclusivity (ODE)	Jun 27, 2025
New Indication (I)	Apr 8, 2023

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Indicated in combination with binimetinib for the treatment of melanoma with a braf mutation; Treatment of melanoma with a braf mutation; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; Braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test; Treatment of melanoma

Dosage: CAPSULE;ORAL

26. List of Breo Ellipta drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281	GLAXO GRP LTD	Manifold for use in medicament dispenser	Mar, 2030 (7 years from now)
US8746242	GLAXO GRP LTD	Medicament dispenser	Oct, 2030 (7 years from now)

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: NA

Dosage: POWDER;INHALATION

27. List of Brexafemme drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8188085	SCYNEXIS	Antifungal agents	Aug, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 1, 2026
Generating Antibiotic Incentives Now (GAIN)	Jun 1, 2031

Drugs and Companies using IBREXAFUNGERP CITRATE ingredient

NCE-1 date: June, 2030

Market Authorisation Date: 01 June, 2021

Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc)

Dosage: TABLET;ORAL

28. List of Breztri Aerosphere drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9463161	ASTRAZENECA AB	Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems	May, 2030 (7 years from now)
US8703806	ASTRAZENECA AB	Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents	May, 2030 (7 years from now)
US8808713	ASTRAZENECA AB	Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems	May, 2030 (7 years from now)
US8324266	ASTRAZENECA AB	Compositions, methods and systems for respiratory delivery of two or more active agents	May, 2030 (7 years from now)
US9415009	ASTRAZENECA AB	Compositions, methods and systems for respiratory delivery of two or more active agents	May, 2030 (7 years from now)
US10716753	ASTRAZENECA AB	Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems	May, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Combination (NC)	Jul 23, 2023

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 23 July, 2020

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

29. List of Brilinta drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8425934	ASTRAZENECA	Pharmaceutical compositions	Apr, 2030 (7 years from now)
US8425934 (Pediatric)	ASTRAZENECA	Pharmaceutical compositions	Oct, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Nov 5, 2023
M	May 9, 2025
Pediatric Exclusivity (PED)	Nov 28, 2023

Drugs and Companies using TICAGRELOR ingredient

Market Authorisation Date: 20 July, 2011

Treatment: NA

Dosage: TABLET;ORAL

30. List of Briviact drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10729653	UCB INC	Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives	Apr, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Aug 27, 2024

Drugs and Companies using BRIVARACETAM ingredient

Market Authorisation Date: 12 May, 2016

Treatment: NA

Dosage: TABLET;ORAL

31. List of Bydureon drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8998876	ASTRAZENECA AB	Ampoule comprising an ampoule holder	Jan, 2030 (6 years from now)
US8721615	ASTRAZENECA AB	Ampoule comprising an ampoule holder	Jan, 2030 (6 years from now)
US8998876 (Pediatric)	ASTRAZENECA AB	Ampoule comprising an ampoule holder	Jul, 2030 (7 years from now)
US8721615 (Pediatric)	ASTRAZENECA AB	Ampoule comprising an ampoule holder	Jul, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Jul 22, 2024
M	Feb 15, 2022
Pediatric Exclusivity (PED)	Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

32. List of Bydureon Bcise drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895033	ASTRAZENECA AB	Sustained release formulations using non-aqueous carriers	Oct, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Jul 22, 2024
M	Feb 15, 2022
Pediatric Exclusivity (PED)	Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; Stimulating insulin release in adults with type 2 diabetes mellitus by administering a pre-mixed exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; Delaying gastric emptying in adults with type 2 diabetes mellitus by administering a pre-mixed exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

33. List of Cabometyx drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11091439	EXELIXIS INC	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer	Jan, 2030 (6 years from now)
US8877776	EXELIXIS INC	(L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Oct, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11098015	EXELIXIS INC	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer	Jan, 2030 (6 years from now)
US11091440	EXELIXIS INC	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer	Jan, 2030 (6 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Sep 17, 2028
New Indication (I)	Sep 17, 2024

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of renal cell carcinoma; Treatment of advanced renal cell carcinoma; Treatment of differentiated thyroid cancer that has progressed following prior vegfr-targeted therapy

Dosage: TABLET;ORAL

34. List of Caldolor drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9012508	CUMBERLAND PHARMS	Administration of intravenous ibuprofen	Sep, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
M	Nov 19, 2024

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 11 June, 2009

Treatment: Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity

Dosage: SOLUTION;INTRAVENOUS

35. List of Cerdelga drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11458119	GENZYME CORP	Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase	Nov, 2030 (7 years from now)

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

Market Authorisation Date: 19 August, 2014

Treatment: NA

Dosage: CAPSULE;ORAL

36. List of Children's Allegra Allergy drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8933097	CHATTEM SANOFI	Fexofenadine suspension formulation	Aug, 2030 (7 years from now)

Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 January, 2011

Treatment: NA

Dosage: SUSPENSION;ORAL

37. List of Combivent Respimat drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8733341	BOEHRINGER INGELHEIM	Atomizer and method of atomizing fluid with a nozzle rinsing mechanism	Oct, 2030 (7 years from now)

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

38. List of Cometriq drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11091439	EXELIXIS	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer	Jan, 2030 (6 years from now)
US8877776	EXELIXIS	(L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Oct, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11091440	EXELIXIS	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer	Jan, 2030 (6 years from now)
US11098015	EXELIXIS	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer	Jan, 2030 (6 years from now)

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 29 November, 2012

Treatment: Method of treating medullary thyroid cancer

Dosage: CAPSULE;ORAL

39. List of Consensi drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9408837	PURPLE BIOTECH	Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs	Feb, 2030 (7 years from now)

Drugs and Companies using AMLODIPINE BESYLATE; CELECOXIB ingredient

Market Authorisation Date: 31 May, 2018

Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate

Dosage: TABLET;ORAL

40. List of Contrave drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8916195	NALPROPION	Sustained release formulation of naltrexone	Feb, 2030 (7 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE;ORAL

41. List of Copiktra drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8193182	SECURA	Substituted isoquinolin-1(2H)-ones, and methods of use thereof	Feb, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 24, 2023
Orphan Drug Exclusivity (ODE)	Sep 24, 2025

Drugs and Companies using DUVELISIB ingredient

NCE-1 date: September, 2022

Market Authorisation Date: 24 September, 2018

Treatment: NA

Dosage: CAPSULE;ORAL

42. List of Cotellic drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803839 (Pediatric)	GENENTECH INC	Azetidines as MEK inhibitors for the treatment of proliferative diseases	May, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Nov 10, 2022
New Indication (I)	Oct 28, 2025
M	Jul 28, 2025
Pediatric Exclusivity (PED)	Jan 28, 2026

Drugs and Companies using COBIMETINIB FUMARATE ingredient

Market Authorisation Date: 10 November, 2015

Treatment: NA

Dosage: TABLET;ORAL

43. List of Cubicin drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138456	CUBIST PHARMS LLC	Lipopeptide compositions and related methods	Nov, 2030 (7 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 12 September, 2003

Treatment: NA

Dosage: POWDER;INTRAVENOUS

44. List of Cycloset drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8877708	VEROSCIENCE	Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders	Jun, 2030 (7 years from now)
US10688155	VEROSCIENCE	Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders	Jun, 2030 (7 years from now)
US9352025	VEROSCIENCE	Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders	Jun, 2030 (7 years from now)
US9895422	VEROSCIENCE	Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders	Jun, 2030 (7 years from now)

Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient

Market Authorisation Date: 05 May, 2009

Treatment: Treatment of type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue wherein the combined therapeutic effect is greater than the additive effect of administering each agent alone; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claims 1 and 10; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 19 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 16 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 2 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 30 wherein the effects are as recited in claim 26; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 27 and wherein the effects are as recited in claim 26; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 17 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 15 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 28 and wherein the effects are as recited in claim 26; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine meylate and a first-phase insulin secretagogue as recited in claims 1 and 3 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 8 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 5 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claims 1 and 11; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1, 17 and 18 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claims 1 and 13; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 22 wherein the effects are as recited in claim 22; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 22 and 24 and wherein the effects are as recited in claim 22; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 29 and wherein the effects are as recited in claim 26; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 6 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 26 and wherein the effects are as recited in claim 26; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 4 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 7 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 22 and 25 and wherein the effects are as recited in claim 22; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claims 1 and 9; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 22 and 23 and wherein the effects are as recited in claim 22; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 56 and wherein the effects are as recited in claim 44; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 31 and wherein the effects are as recited in claim 26; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 44 and wherein the effects are as recited in claims 44 and 54; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 50 wherein the effects are as recited in said claims; Adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 42 and wherein the effects are as recited in claim 42; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 44 and wherein the effects are as recited in claim 44; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 49 and wherein the effects are as recited in claim 44; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 45 and wherein the effects are as recited in claim 44; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 34 wherein the effects are as recited in said claims; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 51 wherein the effects are as recited in said claims; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 32 wherein the effects are as recited in said claims; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 38 and wherein the effects are as recited claim 26; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 39 and wherein the effects are as recited in claim 26; Once daily topical treatment of persistent facial erythema associated with rosacea in adults; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 36 wherein the effects are as recited in said claims; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 48 and wherein the effects are as recited in claim 44; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 33 wherein the effects are as recited in claims; Adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 42 and 43 wherein the effects are as recited in claim 42; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 47 and wherein the effects are as recited in claim 44; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 40 and wherein the effects are as recited in claim 26; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 57 and wherein the effects are as recited in claim 44; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 46 and wherein the effects are as recited in claim 44; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 52 wherein the effects are as recited in said claims; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1-5 and wherein the effects are as recited in claims 1-5; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 7 and wherein the effects are as recited in claim 7; Adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 14-15 and wherein the effects are as recited in claims 14-15; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 9 and wherein the effects are as recited in claim 9; Adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 16-18 and wherein the effects are as recited in claims 16-18; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 10 and wherein the effects are as recited in claim 10; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 6 and wherein the effects are as recited in claim 6; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 19 and wherein the effects are as recited in claim 19; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 12 and wherein the effects are as recited in claim 12; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 11 and wherein the effects are as recited in claim 11; Adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 2 and wherein the effects are as recited in claim 2; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 16-19 and wherein the effects are as recited in claims 16-19; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 8 and wherein the effects are as recited in claim 8; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 14 and wherein the effects are as recited in claim 14; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 3-7 and wherein the effects are as recited in claims 3-7

Dosage: TABLET;ORAL

45. List of Dexilant drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173158	TAKEDA PHARMS USA	Methods of treating gastrointestinal disorders independent of the intake of food	Mar, 2030 (7 years from now)
US8173158 (Pediatric)	TAKEDA PHARMS USA	Methods of treating gastrointestinal disorders independent of the intake of food	Sep, 2030 (7 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Healing of all grades of erosive esophagitis (ee) for up to 8 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months

Dosage: CAPSULE, DELAYED RELEASE;ORAL

46. List of Dextenza drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8563027	OCULAR THERAPEUTIX	Drug delivery through hydrogel plugs	Feb, 2030 (7 years from now)
US8409606	OCULAR THERAPEUTIX	Drug delivery through hydrogel plugs	May, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Oct 7, 2024

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 30 November, 2018

Treatment: Dextenza is approved for the treatment of ocular pain following ophthalmic surgery

Dosage: INSERT;OPHTHALMIC

47. List of Dsuvia drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8574189	ACELRX PHARMS	Storage and dispensing devices for administration of oral transmucosal dosage forms	Mar, 2030 (7 years from now)
US10896751	ACELRX PHARMS	Storage and dispensing devices for administration of oral transmucosal dosage forms	Mar, 2030 (7 years from now)
US8865743	ACELRX PHARMS	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain	Oct, 2030 (7 years from now)
US8202535	ACELRX PHARMS	Small-volume oral transmucosal dosage forms	Oct, 2030 (7 years from now)

Drugs and Companies using SUFENTANIL CITRATE ingredient

Market Authorisation Date: 02 November, 2018

Treatment: Treatment of acute pain

Dosage: TABLET;SUBLINGUAL

48. List of Edarbyclor drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9169238	AZURITY	Solid pharmaceutical composition	Feb, 2030 (7 years from now)

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

Market Authorisation Date: 20 December, 2011

Treatment: NA

Dosage: TABLET;ORAL

49. List of Ella drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10772897	LAB HRA PHARMA	Method for on-demand contraception	Apr, 2030 (7 years from now)
US10159681	LAB HRA PHARMA	Method for on-demand contraception	Apr, 2030 (7 years from now)
US9283233	LAB HRA PHARMA	Method for on-demand contraception	Apr, 2030 (7 years from now)
US8512745	LAB HRA PHARMA	Ulipristal acetate tablets	Jun, 2030 (7 years from now)
US8962603	LAB HRA PHARMA	Method for post coital contraception in overweight or obese female subjects using ulipristal acetate	Jun, 2030 (7 years from now)
US8426392	LAB HRA PHARMA	Method for providing emergency contraception	Jun, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
M	Jun 24, 2024

Drugs and Companies using ULIPRISTAL ACETATE ingredient

Market Authorisation Date: 13 August, 2010

Treatment: A method for contraception, the method comprising administering a tablet comprising 20 mg to 30 mg of ulipristal acetate to a woman within 120 hours after an unprotected intercourse; A method for contraception comprising the step of oral administration a dosage of 20 mg to 30 mg of ulipristal acetate to a woman within 72 hours and up to 120 hours after an unprotected intercourse; Method for contraception to a woman comprising administering to the woman 30mg of ulipristal acetate more than 72 hours and up to 120 hours after an unprotected intercourse; Method for providing post coital contraception to a woman by administering about 30 mg of ulipristal acetate within about 120 hours after intercourse, wherein the woman is overweight having a bmi of 25 to 29.99; Ella is a progesterone agonist/antagonist emergency contraception indicated for the prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. ella can be taken with or without food

Dosage: TABLET;ORAL

50. List of Entereg drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8946262	CUBIST PHARMS	Methods of preventing and treating gastrointestinal dysfunction	Feb, 2030 (7 years from now)

Drugs and Companies using ALVIMOPAN ingredient

Market Authorisation Date: 20 May, 2008

Treatment: A method to accelerate the time to gastrointestinal recovery by administering about 12 mg of alvimopan to the patient from about 30 to 60 minutes prior to surgery

Dosage: CAPSULE;ORAL

51. List of Epclusa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9284342	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Sep, 2030 (7 years from now)
US8618076	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Dec, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Jun 10, 2028
New Strength (NS)	Mar 19, 2023
M	Apr 27, 2025
New Dosing Schedule (D)	Nov 15, 2022
New Patient Population (NPP)	Mar 19, 2023
Pediatric Exclusivity (PED)	May 15, 2023

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Market Authorisation Date: 28 June, 2016

Treatment: For the treatment of hepatitis c

Dosage: TABLET;ORAL

52. List of Erleada drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8445507	JANSSEN BIOTECH	Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases	Sep, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 14, 2023
New Indication (I)	Sep 17, 2022

Drugs and Companies using APALUTAMIDE ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 14 February, 2018

Treatment: Treatment of metastatic castration-sensitive prostate cancer (mcspc); Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc)

Dosage: TABLET;ORAL

53. List of Esbriet drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7816383	GENENTECH INC	Methods of administering pirfenidone therapy	Jan, 2030 (6 years from now)
US8318780	GENENTECH INC	Methods of administering pirfenidone therapy	Jan, 2030 (6 years from now)
US7910610	GENENTECH INC	Methods of administering pirfenidone therapy	Jan, 2030 (6 years from now)
US8754109	GENENTECH INC	Pirfenidone therapy and inducers of cytochrome P450	Jan, 2030 (6 years from now)
US8084475	GENENTECH INC	Pirfenidone therapy and inducers of cytochrome P450	Jan, 2030 (6 years from now)
US8648098	GENENTECH INC	Pirfenidone therapy and inducers of cytochrome P450	Jan, 2030 (6 years from now)
US8013002	GENENTECH INC	Methods of administering pirfenidone therapy	Jan, 2030 (6 years from now)

Drugs and Companies using PIRFENIDONE ingredient

Market Authorisation Date: 11 January, 2017

Treatment: Method for administering pirfenidone to reduce drug interactions with fluvoxamine; Method for administering pirfenidone while avoiding or discontinuing concomitant use of a moderate to strong inhibitor of both cyp1a2 and another cyp enzyme involved in pirfenidone metabolism; Administering pirfenidone while avoiding co-administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone; Discontinuing administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone and then administering pirfenidone; Method for administering pirfenidone to avoid reduced efficacy by avoiding smoking or by avoiding another strong cyp1a2 inducer; Method for administering pirfenidone to avoid reduced efficacy by discontinuing smoking or by discontinuing or avoiding another strong cyp1a2 inducer; Discontinuing smoking to avoid reduced pirfenidone efficacy and then administering pirfenidone; Discontinuing administration of a strong cyp1a2 inducer to avoid reduced pirfenidone efficacy and then administering pirfenidone

Dosage: TABLET;ORAL

54. List of Eucrisa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168614	ANACOR PHARMS INC	Boron-containing small molecules as anti-inflammatory agents	Jan, 2030 (6 years from now)
US8168614 (Pediatric)	ANACOR PHARMS INC	Boron-containing small molecules as anti-inflammatory agents	Jul, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Mar 23, 2023
Pediatric Exclusivity (PED)	Jun 14, 2022

Drugs and Companies using CRISABOROLE ingredient

Market Authorisation Date: 14 December, 2016

Treatment: Method of treating mild to moderate atopic dermatitis.

Dosage: OINTMENT;TOPICAL

55. List of Evomela drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020363	ACROTECH	Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same	May, 2030 (7 years from now)
US10864183	ACROTECH	Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same	May, 2030 (7 years from now)
US10940128	ACROTECH	Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same	Jun, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Mar 10, 2023

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 10 March, 2016

Treatment: For high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma

Dosage: POWDER;INTRAVENOUS

56. List of Exem Foam Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034300	GISKIT	Composition and method for medical imaging of body cavities	Oct, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Nov 7, 2024

Drugs and Companies using AIR POLYMER-TYPE A ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 07 November, 2019

Treatment: Use in sonohysterosalpinography to assess fallopian tube patency

Dosage: FOAM;INTRAUTERINE

57. List of Fabior drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10568859	MAYNE PHARMA	Topical foam composition	Feb, 2030 (7 years from now)
US10688071	MAYNE PHARMA	Topical foam composition	Feb, 2030 (7 years from now)
US8808716	MAYNE PHARMA	Topical foam composition	Feb, 2030 (7 years from now)

Drugs and Companies using TAZAROTENE ingredient

Market Authorisation Date: 11 May, 2012

Treatment: Topical treatment of acne vulgaris in patients 12 years of age or older

Dosage: AEROSOL, FOAM;TOPICAL

58. List of Fanapt drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9157121	VANDA PHARMS INC	Method of treatment based on polymorphisms of the KCNQ1 gene	Apr, 2030 (7 years from now)
US8652776	VANDA PHARMS INC	Prediction of QT prolongation based on SNP genotype	Aug, 2030 (7 years from now)
US8999638	VANDA PHARMS INC	Method of treatment based on polymorphisms of the KCNQ1 gene	Oct, 2030 (7 years from now)
US9074255	VANDA PHARMS INC	Method of predicting a predisposition to QT prolongation	Dec, 2030 (7 years from now)

Drugs and Companies using ILOPERIDONE ingredient

Market Authorisation Date: 06 May, 2009

Treatment: Dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone; Dosage modification to reduce the risk associated with qt prolongation not induced by other drugs during treatment with iloperidone

Dosage: TABLET;ORAL

59. List of Farxiga drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8721615	ASTRAZENECA AB	Ampoule comprising an ampoule holder	Jan, 2030 (6 years from now)
US8685934	ASTRAZENECA AB	Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof	May, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
M	Feb 22, 2022
New Indication (I)	Oct 18, 2022

Drugs and Companies using DAPAGLIFLOZIN ingredient

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone

Dosage: TABLET;ORAL

60. List of Flolipid drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597289	TCG FLUENT PHARMA	Liquid oral simvastatin compositions	Feb, 2030 (7 years from now)

Drugs and Companies using SIMVASTATIN ingredient

Market Authorisation Date: 21 April, 2016

Treatment: NA

Dosage: SUSPENSION;ORAL

61. List of Fosrenol drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9023397	TAKEDA PHARMS USA	Capsule and powder formulations containing lanthanum compounds	Dec, 2030 (7 years from now)
US8980327	TAKEDA PHARMS USA	Capsule and powder formulations containing lanthanum compounds	Dec, 2030 (7 years from now)

Drugs and Companies using LANTHANUM CARBONATE ingredient

Market Authorisation Date: 24 September, 2014

Treatment: NA

Dosage: POWDER;ORAL

62. List of Fyarro drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10206887	AADI	Prion free nanoparticle compositions and methods of making thereof	Apr, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Nov 22, 2024

Drugs and Companies using SIROLIMUS ingredient

Market Authorisation Date: 22 November, 2021

Treatment: NA

Dosage: POWDER;INTRAVENOUS

63. List of Gemtesa drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8247415	UROVANT	Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists	Dec, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 23, 2025

Drugs and Companies using VIBEGRON ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 23 December, 2020

Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency

Dosage: TABLET;ORAL

64. List of Genosyl drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103669	VERO BIOTECH	Nitric oxide therapies	Jun, 2030 (7 years from now)
US8607785	VERO BIOTECH	Systems and devices for generating nitric oxide	Jul, 2030 (7 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: NA

Dosage: GAS;INHALATION

65. List of Genvoya drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9891239 (Pediatric)	GILEAD SCIENCES INC	Modulators of pharmacokinetic properties of therapeutics	Mar, 2030 (7 years from now)
US8148374 (Pediatric)	GILEAD SCIENCES INC	Modulators of pharmacokinetic properties of therapeutics	Mar, 2030 (7 years from now)
US8633219	GILEAD SCIENCES INC	Combination therapy	Apr, 2030 (7 years from now)
US8633219 (Pediatric)	GILEAD SCIENCES INC	Combination therapy	Oct, 2030 (7 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 05 November, 2015

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

66. List of Gilotrif drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8426586 (Pediatric)	BOEHRINGER INGELHEIM	Process for preparing amino crotonyl compounds	Apr, 2030 (7 years from now)
US8545884 (Pediatric)	BOEHRINGER INGELHEIM	Solid pharmaceutical formulations comprising BIBW 2992	Jun, 2030 (7 years from now)
US10004743	BOEHRINGER INGELHEIM	Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient	Jul, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Jan 12, 2025
M	Apr 7, 2025
Pediatric Exclusivity (PED)	Oct 15, 2023

Drugs and Companies using AFATINIB DIMALEATE ingredient

Market Authorisation Date: 12 July, 2013

Treatment: NA

Dosage: TABLET;ORAL

67. List of Gimoti drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8334281	EVOKE PHARMA INC	Nasal formulations of metoclopramide	May, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Jun 19, 2023

Drugs and Companies using METOCLOPRAMIDE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 June, 2020

Treatment: Nasal administration of metoclopramide for treatment of diabetic gastroparesis

Dosage: SPRAY, METERED;NASAL

68. List of Gocovri drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9877933	ADAMAS PHARMA	Method of administering amantadine prior to a sleep period	Dec, 2030 (7 years from now)
US8741343	ADAMAS PHARMA	Method of administering amantadine prior to a sleep period	Dec, 2030 (7 years from now)
US11197835	ADAMAS PHARMA	Method of administering amantadine prior to a sleep period	Dec, 2030 (7 years from now)
US9867792	ADAMAS PHARMA	Method of administering amantadine prior to a sleep period	Dec, 2030 (7 years from now)
US9867791	ADAMAS PHARMA	Method of administering amantadine prior to a sleep period	Dec, 2030 (7 years from now)
US9867793	ADAMAS PHARMA	Method of administering amantadine prior to a sleep period	Dec, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Aug 24, 2024

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 August, 2017

Treatment: Treatment of dyskinesia and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

69. List of Harvoni drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8822430	GILEAD SCIENCES INC	Antiviral compounds	May, 2030 (7 years from now)
US8088368	GILEAD SCIENCES INC	Antiviral compounds	May, 2030 (7 years from now)
US9284342	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Sep, 2030 (7 years from now)
US8618076	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Dec, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8273341	GILEAD SCIENCES INC	Antiviral compounds	May, 2030 (7 years from now)
US8841278	GILEAD SCIENCES INC	Antiviral compounds	May, 2030 (7 years from now)
US9511056	GILEAD SCIENCES INC	Antiviral compounds	May, 2030 (7 years from now)
US8088368 (Pediatric)	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2030 (7 years from now)
US9511056 (Pediatric)	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2030 (7 years from now)
US8822430 (Pediatric)	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2030 (7 years from now)
US8841278 (Pediatric)	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2030 (7 years from now)
US8273341 (Pediatric)	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Dosing Schedule (D)	Nov 15, 2022
Orphan Drug Exclusivity (ODE)	Apr 7, 2024
Pediatric Exclusivity (PED)	Oct 7, 2024

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Market Authorisation Date: 10 October, 2014

Treatment: For the treatment of hepatitis c

Dosage: TABLET;ORAL

70. List of Ibsrela drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9006281	ARDELYX INC	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders	May, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 12, 2024

Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient

NCE-1 date: September, 2023

Market Authorisation Date: 12 September, 2019

Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor

Dosage: TABLET;ORAL

71. List of Idhifa drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610125	CELGENE CORP	Methods and compositions for cell-proliferation-related disorders	Jun, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Aug 1, 2024
New Chemical Entity Exclusivity (NCE)	Aug 1, 2022

Drugs and Companies using ENASIDENIB MESYLATE ingredient

NCE-1 date: August, 2021

Market Authorisation Date: 01 August, 2017

Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation

Dosage: TABLET;ORAL

72. List of Ilevro drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9662398	NOVARTIS	Carboxylvinyl polymer-containing nanoparticle suspensions	Dec, 2030 (7 years from now)

Drugs and Companies using NEPAFENAC ingredient

Market Authorisation Date: 16 October, 2012

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

73. List of Implanon drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9757552	ORGANON	Applicator for inserting an implant	Jul, 2030 (7 years from now)

Drugs and Companies using ETONOGESTREL ingredient

Market Authorisation Date: 17 July, 2006

Treatment: Prevention of pregnancy

Dosage: IMPLANT;IMPLANTATION

74. List of Impoyz drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9956231	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (7 years from now)
US10064875	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (7 years from now)
US10588914	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (7 years from now)

Drugs and Companies using CLOBETASOL PROPIONATE ingredient

Market Authorisation Date: 28 November, 2017

Treatment: Treatment of moderate plaque psoriasis; Treatment of plaque psoriasis in patients 18 years of age or older; Psoriasis; Twice daily topical treatment of moderate to severe plaque psoriasis.; Treatment of plaque psoriasis; Plaque psoriasis; Treatment of moderate to severe plaque psoriasis in patients 18 years of age or older

Dosage: CREAM;TOPICAL

75. List of Incruse Ellipta drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281	GLAXO GRP ENGLAND	Manifold for use in medicament dispenser	Mar, 2030 (7 years from now)
US8746242	GLAXO GRP ENGLAND	Medicament dispenser	Oct, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
M	Jun 9, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE ingredient

Market Authorisation Date: 30 April, 2014

Treatment: NA

Dosage: POWDER;INHALATION

76. List of Inlyta drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8791140	PF PRISM CV	Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals	Dec, 2030 (7 years from now)

Drugs and Companies using AXITINIB ingredient

Market Authorisation Date: 27 January, 2012

Treatment: NA

Dosage: TABLET;ORAL

77. List of Inqovi drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8268800	OTSUKA	Certain compounds, compositions and methods	Aug, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 7, 2025
Orphan Drug Exclusivity (ODE)	Jul 7, 2027

Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient

NCE-1 date: July, 2024

Market Authorisation Date: 07 July, 2020

Treatment: Treatment of chronic myelomonocytic leukemia; Treatment of myelodysplastic syndrome; Method for inhibiting cytidine deaminase by administering cedazuridine; Method for inhibiting degradation of a cda substrate by administering cedazuridine

Dosage: TABLET;ORAL

78. List of Intrarosa drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8957054	MILLICENT	Pharmaceutical compositions	Jan, 2030 (6 years from now)

Drugs and Companies using PRASTERONE ingredient

Market Authorisation Date: 16 November, 2016

Treatment: Intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause

Dosage: INSERT;VAGINAL

79. List of Isentress drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649311	MERCK SHARP DOHME	Solid pharmaceutical compositions containing an integrase inhibitor	Oct, 2030 (7 years from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 12 October, 2007

Treatment: NA

Dosage: TABLET;ORAL

80. List of Jatenzo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10617696	CLARUS	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	Apr, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11426416	CLARUS	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	Apr, 2030 (7 years from now)
US11179403	CLARUS	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	Apr, 2030 (7 years from now)
US10543219	CLARUS	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	Apr, 2030 (7 years from now)
US8778916	CLARUS	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	Apr, 2030 (7 years from now)
US8492369	CLARUS	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	Dec, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Mar 27, 2022

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 27 March, 2019

Treatment: A method of treating testosterone deficiency in men; Method of treating testosterone deficiency

Dosage: CAPSULE;ORAL

81. List of Jentadueto drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9155705	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	May, 2030 (7 years from now)
US8846695	BOEHRINGER INGELHEIM	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor	Jun, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
M	Jul 3, 2022

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 2012

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin

Dosage: TABLET;ORAL

82. List of Jentadueto Xr drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9155705	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	May, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
M	Jul 3, 2022

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 May, 2016

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

83. List of Jevtana Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8927592	SANOFI AVENTIS US	Antitumoral use of cabazitaxel	Oct, 2030 (7 years from now)
US10716777	SANOFI AVENTIS US	Antitumoral use of cabazitaxel	Oct, 2030 (7 years from now)
US10583110	SANOFI AVENTIS US	Antitumoral use of cabazitaxel	Oct, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
M	Dec 18, 2023

Drugs and Companies using CABAZITAXEL ingredient

Market Authorisation Date: 17 June, 2010

Treatment: Increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen that includes an antihistamine, a corticosteroid, and an h2-antagonist; Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering 20 to 25 mg/m2 cabazitaxel after a premedication regimen that includes an h2-antagonist; Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg dexamethasone, and an h2-agonist

Dosage: SOLUTION;INTRAVENOUS

84. List of Jublia drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9861698	BAUSCH	Compositions and methods for treating diseases of the nail	Jul, 2030 (7 years from now)
US8039494	BAUSCH	Compositions and methods for treating diseases of the nail	Jul, 2030 (7 years from now)
US10105444	BAUSCH	Compositions and methods for treating diseases of the nail	Jul, 2030 (7 years from now)
US8486978	BAUSCH	Compositions and methods for treating diseases of the nail	Oct, 2030 (7 years from now)
US9302009	BAUSCH	Compositions and methods for treating diseases of the nail	Oct, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Apr 27, 2023

Drugs and Companies using EFINACONAZOLE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: Antimycotic uses, specifically treatment of onychomycosis

Dosage: SOLUTION;TOPICAL

85. List of Jynarque drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10905694	OTSUKA	Pharmaceutical solid preparation comprising benzazepines and production method thereof	Apr, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Apr 23, 2025

Drugs and Companies using TOLVAPTAN ingredient

Market Authorisation Date: 23 April, 2018

Treatment: NA

Dosage: TABLET;ORAL

86. List of Kengreal drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9427448	CHIESI	Methods of treating, reducing the incidence of, and/or preventing ischemic events	Nov, 2030 (7 years from now)

Drugs and Companies using CANGRELOR ingredient

Market Authorisation Date: 22 June, 2015

Treatment: Method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and continuous infusion of 4 ug/kg/min for at least 2 hours or the duration of the pci

Dosage: POWDER;INTRAVENOUS

87. List of Kimyrsa drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9682061	MELINTA THERAP	Methods of treating bacterial infections using oritavancin	Apr, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Mar 12, 2024
New Chemical Entity Exclusivity (NCE)	Aug 6, 2019
Generating Antibiotic Incentives Now (GAIN)	Aug 6, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 12 March, 2021

Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent

Dosage: POWDER;INTRAVENOUS

88. List of Kisqali drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8685980	NOVARTIS	Pyrrolopyrimidine compounds and their uses	May, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Mar 13, 2022
New Patient Population (NPP)	Dec 10, 2024

Drugs and Companies using RIBOCICLIB SUCCINATE ingredient

NCE-1 date: March, 2021

Market Authorisation Date: 13 March, 2017

Treatment: NA

Dosage: TABLET;ORAL

89. List of Kisqali Femara Co-pack (copackaged) drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8685980	NOVARTIS	Pyrrolopyrimidine compounds and their uses	May, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Mar 13, 2022
New Patient Population (NPP)	Dec 10, 2024

Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient

NCE-1 date: March, 2021

Market Authorisation Date: 04 May, 2017

Treatment: NA

Dosage: TABLET;ORAL

90. List of Kovanaze drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9308191	ST RENATUS	Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration	Apr, 2030 (7 years from now)
US8580282	ST RENATUS	Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration	Apr, 2030 (7 years from now)

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 29 June, 2016

Treatment: Method of anesthetizing at least a portion of the maxillary dental arch

Dosage: SPRAY, METERED;NASAL

91. List of Kybella drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101593	KYTHERA BIOPHARMS	Formulations of deoxycholic acid and salts thereof	Mar, 2030 (7 years from now)
US10500214	KYTHERA BIOPHARMS	Formulations of deoxycholic acid and salts thereof	Mar, 2030 (7 years from now)
US8367649	KYTHERA BIOPHARMS	Formulations of deoxycholic acid and salts thereof	Mar, 2030 (7 years from now)
US8653058	KYTHERA BIOPHARMS	Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits	Mar, 2030 (7 years from now)

Drugs and Companies using DEOXYCHOLIC ACID ingredient

Market Authorisation Date: 29 April, 2015

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

92. List of Kynmobi drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9283219	SUNOVION PHARMS INC	Sublingual films	Jun, 2030 (7 years from now)
US9669019	SUNOVION PHARMS INC	Sublingual apomorphine	Jun, 2030 (7 years from now)
US9669021	SUNOVION PHARMS INC	Sublingual apomorphine	Jun, 2030 (7 years from now)
US9326981	SUNOVION PHARMS INC	Sublingual apomorphine	Jun, 2030 (7 years from now)
US9044475	SUNOVION PHARMS INC	Sublingual apomorphine	Jun, 2030 (7 years from now)
US10420763	SUNOVION PHARMS INC	Sublingual apomorphine	Jun, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	May 21, 2023

Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 May, 2020

Treatment: Treatment of 'off' episodes in patients with parkinson's disease

Dosage: FILM;SUBLINGUAL

93. List of Kyzatrex drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10576090	MARIUS PHARMS LLC	Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols	Dec, 2030 (7 years from now)
US10576089	MARIUS PHARMS LLC	Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols	Dec, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Jul 27, 2025

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 27 July, 2022

Treatment: Method of treating testosterone deficiency

Dosage: CAPSULE;ORAL

94. List of Lonhala Magnair Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9789270	SUNOVION RESP	Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized	Oct, 2030 (7 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION;INHALATION

95. List of Lumify drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8293742	BAUSCH AND LOMB INC	Preferential vasoconstriction compositions and methods of use	Jul, 2030 (7 years from now)
US9259425	BAUSCH AND LOMB INC	Compositions and methods for eye whitening	Jul, 2030 (7 years from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 22 December, 2017

Treatment: Relieves redness of the eye due to minor eye irritations

Dosage: SOLUTION/DROPS;OPHTHALMIC

96. List of Mavyret drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039754	ABBVIE INC	Anti-viral compounds	Jun, 2030 (7 years from now)
US10028937	ABBVIE INC	Anti-viral compounds	Jun, 2030 (7 years from now)
US9586978	ABBVIE INC	Anti-viral compounds	Nov, 2030 (7 years from now)
US10028937 (Pediatric)	ABBVIE INC	Anti-viral compounds	Dec, 2030 (7 years from now)
US10039754 (Pediatric)	ABBVIE INC	Anti-viral compounds	Dec, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Aug 3, 2022
M	Apr 10, 2023
New Dosing Schedule (D)	Sep 26, 2022
Orphan Drug Exclusivity (ODE)	Jun 10, 2028
Pediatric Exclusivity (PED)	Mar 26, 2023

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

NCE-1 date: March, 2022

Market Authorisation Date: 10 June, 2021

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg

Dosage: PELLETS;ORAL

97. List of Mayzent drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492441	NOVARTIS	Dosage regimen of an S1P receptor agonist	Nov, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Mar 26, 2024
M	Mar 1, 2025

Drugs and Companies using SIPONIMOD FUMARIC ACID ingredient

NCE-1 date: March, 2023

Market Authorisation Date: 26 March, 2019

Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose

Dosage: TABLET;ORAL

98. List of Mekinist drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8703781	NOVARTIS	Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors	Oct, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8952018	NOVARTIS	Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors	Oct, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Jun 22, 2024
M	Oct 6, 2022
New Indication (I)	Jun 22, 2025

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Market Authorisation Date: 29 May, 2013

Treatment: Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test; Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options; Mekinist is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Mekinist is indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test; Mekinist in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma

Dosage: TABLET;ORAL

99. List of Mektovi drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9850229	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US10005761	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US9593100	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 27, 2023
Orphan Drug Exclusivity (ODE)	Jun 27, 2025

Drugs and Companies using BINIMETINIB ingredient

NCE-1 date: June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Indicated in combination with encorafenib for the treatment of melanoma with a braf mutation; Indicated in combination with encorafenib for the treatment of melanoma

Dosage: TABLET;ORAL

100. List of Milprosa drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8580293	FERRING PHARMS INC	Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof	Jan, 2030 (6 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Apr 29, 2023

Drugs and Companies using PROGESTERONE ingredient

Market Authorisation Date: 29 April, 2020

Treatment: Method of supporting embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women

Dosage: SYSTEM;VAGINAL

101. List of Minivelle drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8231906	NOVEN	Transdermal estrogen device and delivery	Jul, 2030 (7 years from now)

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 29 October, 2012

Treatment: NA

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

102. List of Mulpleta drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8530668	SHIONOGI INC	Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor	Jan, 2030 (6 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 31, 2023

Drugs and Companies using LUSUTROMBOPAG ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 31 July, 2018

Treatment: NA

Dosage: TABLET;ORAL

103. List of Myoview drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549999	GE HEALTHCARE	Radiopharmaceutical composition	Mar, 2030 (7 years from now)

Drugs and Companies using TECHNETIUM TC-99M TETROFOSMIN KIT ingredient

Market Authorisation Date: 09 February, 1996

Treatment: NA

Dosage: INJECTABLE;INJECTION

104. List of Myrbetriq drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10842780 (Pediatric)	APGDI	Pharmaceutical composition for modified release	Mar, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Mar 25, 2024
Pediatric Exclusivity (PED)	Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

Market Authorisation Date: 28 June, 2012

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

105. List of Nerlynx drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7399865	PUMA BIOTECH	Protein tyrosine kinase enzyme inhibitors	Dec, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9211291	PUMA BIOTECH	Treatment regimen utilizing neratinib for breast cancer	Mar, 2030 (7 years from now)
US8790708	PUMA BIOTECH	Coated tablet formulations and uses thereof	Nov, 2030 (7 years from now)
US8518446	PUMA BIOTECH	Coated tablet formulations and uses thereof	Nov, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 17, 2022
New Indication (I)	Feb 25, 2023
New Dosing Schedule (D)	Jun 28, 2024

Drugs and Companies using NERATINIB MALEATE ingredient

NCE-1 date: July, 2021

Market Authorisation Date: 17 July, 2017

Treatment: Extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab base therapy; Extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy; Use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the metastatic setting

Dosage: TABLET;ORAL

106. List of Neupro drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130589	UCB INC	Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine	Dec, 2030 (7 years from now)
US10350174	UCB INC	Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine	Dec, 2030 (7 years from now)

Drugs and Companies using ROTIGOTINE ingredient

Market Authorisation Date: 09 May, 2007

Treatment: NA

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

107. List of Nithiodote drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9345724	HOPE PHARMS	Sodium thiosulfate-containing pharmaceutical compositions	Jul, 2030 (7 years from now)
US9585912	HOPE PHARMS	Sodium thiosulfate-containing pharmaceutical compositions	Jul, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9687506	HOPE PHARMS	Sodium nitrite-containing pharmaceutical compositions	Feb, 2030 (7 years from now)
US10479686	HOPE PHARMS	Sodium thiosulfate-containing pharmaceutical compositions	Jul, 2030 (7 years from now)

Drugs and Companies using SODIUM NITRITE; SODIUM THIOSULFATE ingredient

Market Authorisation Date: 14 January, 2011

Treatment: Sodium nitrite injection is administered by intravenous injection; Sodium nitrite injection is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning; Sodium thiosulfate injection is administered by intravenous injection; Sodium thiosulfate injection is indicated for sequential use with sodium nitrite for the treatment of acute cyanide poisoning

Dosage: SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS

108. List of Nocdurna drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9974826	FERRING PHARMS INC	Methods comprising desmopressin	Apr, 2030 (7 years from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Market Authorisation Date: 21 June, 2018

Treatment: Treatment of nocturia due to nocturnal polyuria in adults; Treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration

Dosage: TABLET;SUBLINGUAL

109. List of Noctiva drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539302	SERENITY PHARMS LLC	Safe desmopressin administration	Jun, 2030 (7 years from now)
US11419914	SERENITY PHARMS LLC	Safe desmopressin administration	Jun, 2030 (7 years from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Market Authorisation Date: 03 March, 2017

Treatment: Treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void by inducing an antidiuretic effect by intranasally administering a plume of droplets comprising a dose of about 0.05-5 mcg desmopressin

Dosage: SPRAY, METERED;NASAL

110. List of Nubeqa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9657003	BAYER HEALTHCARE	Androgen receptor modulating compounds	Oct, 2030 (7 years from now)
US8975254	BAYER HEALTHCARE	Androgen receptor modulating compounds	Oct, 2030 (7 years from now)
US11046713	BAYER HEALTHCARE	Androgen receptor modulating compounds	Oct, 2030 (7 years from now)
US10711013	BAYER HEALTHCARE	Androgen receptor modulating compounds	Oct, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 30, 2024
New Indication (I)	Aug 5, 2025

Drugs and Companies using DAROLUTAMIDE ingredient

NCE-1 date: July, 2023

Market Authorisation Date: 30 July, 2019

Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer

Dosage: TABLET;ORAL

111. List of Nuplazid drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7601740	ACADIA PHARMS INC	Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Apr, 2030 (7 years from now)

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

Market Authorisation Date: 28 June, 2018

Treatment: NA

Dosage: CAPSULE;ORAL

112. List of Nuzyra drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8383610	PARATEK PHARMS INC	Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline	Sep, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Oct 2, 2023
Generating Antibiotic Incentives Now (GAIN)	Oct 2, 2028

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

NCE-1 date: October, 2027

Market Authorisation Date: 02 October, 2018

Treatment: NA

Dosage: TABLET;ORAL

113. List of Olumiant drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8158616	ELI LILLY AND CO	Azetidine and cyclobutane derivatives as JAK inhibitors	Jun, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	May 10, 2025
New Chemical Entity Exclusivity (NCE)	May 31, 2023

Drugs and Companies using BARICITINIB ingredient

NCE-1 date: May, 2022

Market Authorisation Date: 31 May, 2018

Treatment: NA

Dosage: TABLET;ORAL

114. List of Ongentys drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10071085	NEUROCRINE	Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof	Mar, 2030 (7 years from now)
US10583130	NEUROCRINE	Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof	Mar, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 24, 2025

Drugs and Companies using OPICAPONE ingredient

NCE-1 date: April, 2024

Market Authorisation Date: 24 April, 2020

Treatment: Method of treating parkinson's disease

Dosage: CAPSULE;ORAL

115. List of Onpattro drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802644	ALNYLAM PHARMS INC	Lipid formulation	Oct, 2030 (7 years from now)
US8158601	ALNYLAM PHARMS INC	Lipid formulation	Nov, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Aug 10, 2025
New Chemical Entity Exclusivity (NCE)	Aug 10, 2023

Drugs and Companies using PATISIRAN SODIUM ingredient

NCE-1 date: August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis

Dosage: SOLUTION;INTRAVENOUS

116. List of Onureg drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846628	CELGENE CORP	Oral formulations of cytidine analogs and methods of use thereof	Jun, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Sep 1, 2023
Orphan Drug Exclusivity (ODE)	Sep 1, 2027

Drugs and Companies using AZACITIDINE ingredient

Market Authorisation Date: 01 September, 2020

Treatment: Continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not able to complete intensive curative therapy

Dosage: TABLET;ORAL

117. List of Onzetra Xsail drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8899229	CURRAX	Powder delivery devices	Aug, 2030 (7 years from now)
US9649456	CURRAX	Nasal administration	Oct, 2030 (7 years from now)
US8978647	CURRAX	Nasal delivery	Dec, 2030 (7 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: Acute treatment of migraine; Treatment of migraine via delivery of sumatriptan via the nasal cavity; Acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device

Dosage: POWDER;NASAL

118. List of Orbactiv drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9682061	MELINTA THERAP	Methods of treating bacterial infections using oritavancin	Apr, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Aug 6, 2019
Generating Antibiotic Incentives Now (GAIN)	Aug 6, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 06 August, 2014

Treatment: Treatment of bacterial skin and skin structure infections

Dosage: POWDER;INTRAVENOUS

119. List of Orenitram drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410169	UNITED THERAP	Compounds and methods for delivery of prostacyclin analogs	Feb, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Oct 18, 2022
Orphan Drug Exclusivity (ODE)	Oct 18, 2026

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Market Authorisation Date: 20 December, 2013

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

120. List of Orkambi drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8507534	VERTEX PHARMS INC	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid	Sep, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8716338	VERTEX PHARMS INC	Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid	Sep, 2030 (7 years from now)
US8993600	VERTEX PHARMS INC	Modulators of ATP-binding cassette transporters	Dec, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Sep 28, 2023

Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient

Market Authorisation Date: 02 July, 2015

Treatment: Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using the dosage unit of claim 1 of u.s. patent no. 8,716,338; Method of treating cystic fibrosis in patients who have the f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Dosage: TABLET;ORAL

121. List of Osmolex Er drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8252331	ADAMAS PHARMA	Osmotic device containing amantadine and an osmotic salt	Mar, 2030 (7 years from now)

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 February, 2018

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

122. List of Otiprio drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8318817	ALK ABELLO	Controlled release antimicrobial compositions and methods for the treatment of otic disorders	Apr, 2030 (7 years from now)

Drugs and Companies using CIPROFLOXACIN ingredient

Market Authorisation Date: 10 December, 2015

Treatment: Treatment of otic infection or inflammation

Dosage: INJECTABLE, SUSPENSION;OTIC

123. List of Otovel drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8932610	LABORATORIOS SALVAT	Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation	Mar, 2030 (7 years from now)

Drugs and Companies using CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE ingredient

Market Authorisation Date: 29 April, 2016

Treatment: Treatment of acute otitis media

Dosage: SOLUTION/DROPS;OTIC

124. List of Otrexup drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8945063	OTTER PHARMS	Hazardous agent injection system	Mar, 2030 (7 years from now)
US8579865	OTTER PHARMS	Hazardous agent injection system	Mar, 2030 (7 years from now)
US9421333	OTTER PHARMS	Hazardous agent injection system	Mar, 2030 (7 years from now)
US11497753	OTTER PHARMS	Hazardous agent injection system	Mar, 2030 (7 years from now)
US8480631	OTTER PHARMS	Hazardous agent injection system	Mar, 2030 (7 years from now)

Drugs and Companies using METHOTREXATE ingredient

Market Authorisation Date: 11 October, 2013

Treatment: Subcutaneous injection of methotrexate

Dosage: SOLUTION;SUBCUTANEOUS

125. List of Oxycontin drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8894987	PURDUE PHARMA LP	Tamper resistant dosage forms	Mar, 2030 (7 years from now)

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 April, 2010

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

126. List of Parsabiv drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9278995	KAI PHARMS INC	Therapeutic agents for reducing parathyroid hormone levels	Jul, 2030 (7 years from now)
US9701712	KAI PHARMS INC	Therapeutic agents for reducing parathyroid hormone levels	Jul, 2030 (7 years from now)
US8377880	KAI PHARMS INC	Therapeutic agents for reducing parathyroid hormone levels	Jul, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 7, 2022

Drugs and Companies using ETELCALCETIDE ingredient

NCE-1 date: February, 2021

Market Authorisation Date: 07 February, 2017

Treatment: A method of treating secondary hyperparathyroidism (shpt)

Dosage: SOLUTION;INTRAVENOUS

127. List of Pennsaid drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8546450	HORIZON	Treatment of pain with topical diclofenac compounds	Aug, 2030 (7 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Market Authorisation Date: 16 January, 2014

Treatment: Combination use of topical diclofenac on the knee and administration of an oral nsaid.; Use of topical diclofenac on the knee and a second topical agent selected from sunscreen and insect repellant

Dosage: SOLUTION;TOPICAL

128. List of Pennsaid drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8546450	NUVO PHARMS INC	Treatment of pain with topical diclofenac compounds	Aug, 2030 (7 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Market Authorisation Date: 04 November, 2009

Dosage: SOLUTION;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
50 mg/5 mL	12 May, 2020	2		21 Feb, 2026
10 mg/mL	12 May, 2020	1		21 Feb, 2026
10 mg, 25 mg, 50 mg, 75 mg and 100 mg	12 May, 2020	7	09 Jun, 2022	21 Feb, 2026	Eligible

Strength	Dosage	Availability
0.1MG/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription
0.2MG/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
90 mg	20 Jul, 2015	16	04 Sep, 2018	17 Apr, 2030	Eligible
60 mg	30 Sep, 2015	3	04 Sep, 2018	17 Apr, 2030	Eligible

Strength	Dosage	Availability
2MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	Discontinued
2MG	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	Discontinued

Strength	Dosage	Availability
EQ 20MG BASE	TABLET;ORAL	Prescription
EQ 40MG BASE	TABLET;ORAL	Prescription
EQ 60MG BASE	TABLET;ORAL	Prescription

Strength	Dosage	Availability
400MG/4ML (100MG/ML)	SOLUTION;INTRAVENOUS	Discontinued
800MG/8ML (100MG/ML)	SOLUTION;INTRAVENOUS	Prescription
800MG/200ML (4MG/ML)	SOLUTION;INTRAVENOUS	Prescription

Strength	Dosage	Availability
EQ 2.5MG BASE;200MG	TABLET;ORAL	Discontinued
EQ 5MG BASE;200MG	TABLET;ORAL	Discontinued
EQ 10MG BASE;200MG	TABLET;ORAL	Discontinued

Strength	Dosage	Availability
250MG/VIAL	POWDER;INTRAVENOUS	Discontinued
500MG/VIAL	POWDER;INTRAVENOUS	Prescription

Strength	Dosage	Availability
30MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription
60MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription

Strength	Dosage	Availability
EQ 40MG MEDOXOMIL;12.5MG	TABLET;ORAL	Prescription
EQ 40MG MEDOXOMIL;25MG	TABLET;ORAL	Prescription

Strength	Dosage	Availability
200MG;50MG	TABLET;ORAL	Prescription
400MG;100MG	TABLET;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
267 mg	15 Oct, 2018	9	03 Jan, 2022	30 Aug, 2033	Eligible
267 mg and 801 mg	15 Oct, 2018	17	25 Jan, 2022	30 Aug, 2033	Eligible
534 mg	15 Oct, 2018	2	19 Jul, 2022	30 Aug, 2033	Eligible

Strength	Dosage	Availability
267MG	TABLET;ORAL	Prescription
534MG	TABLET;ORAL	Discontinued
801MG	TABLET;ORAL	Prescription

Strength	Dosage	Availability
20MG/5ML	SUSPENSION;ORAL	Prescription
40MG/5ML	SUSPENSION;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
500 mg, 750 mg and 1000 mg	27 Oct, 2008	3	11 Aug, 2017	26 Aug, 2024	Deferred
750 mg and 1000 mg	25 Nov, 2015	1		01 Dec, 2030	Extinguished

Strength	Dosage	Availability
EQ 1GM BASE	POWDER;ORAL	Prescription
EQ 750MG BASE	POWDER;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
137 mg	16 Jan, 2018	1		02 Dec, 2030
68.5 mg	30 Apr, 2020	1		04 Dec, 2034

Strength	Dosage	Availability
EQ 68.5MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 137MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

Strength	Dosage	Availability
45MG;200MG	TABLET;ORAL	Prescription
90MG;400MG	TABLET;ORAL	Prescription

Strength	Dosage	Availability
EQ 50MG BASE	TABLET;ORAL	Prescription
EQ 100MG BASE	TABLET;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
400 mg	12 Oct, 2011	1		11 Mar, 2029
600 mg	21 Oct, 2022	1		30 Mar, 2032

Pharsight

Drug Patents Expiring in 2030

1. List of Abilify Mycite Kit drug patents

2. List of Acetaminophen drug patents

3. List of Acuvue Theravision With Ketotifen drug patents

4. List of Akynzeo drug patents

5. List of Akynzeo drug patents

6. List of Alecensa drug patents

7. List of Amondys 45 drug patents

8. List of Amzeeq drug patents

9. List of Anjeso drug patents

10. List of Anoro Ellipta drug patents

11. List of Apadaz drug patents

12. List of Apriso drug patents

13. List of Aptiom drug patents

14. List of Aristada drug patents

15. List of Aristada Initio Kit drug patents

16. List of Arnuity Ellipta drug patents

17. List of Atrovent Hfa drug patents

18. List of Aubagio drug patents

19. List of Auryxia drug patents

20. List of Avycaz drug patents

21. List of Besivance drug patents

22. List of Bevespi Aerosphere drug patents

23. List of Bevyxxa drug patents

24. List of Beyaz drug patents

25. List of Braftovi drug patents

26. List of Breo Ellipta drug patents

27. List of Brexafemme drug patents

28. List of Breztri Aerosphere drug patents

29. List of Brilinta drug patents

30. List of Briviact drug patents

31. List of Bydureon drug patents

32. List of Bydureon Bcise drug patents

33. List of Cabometyx drug patents

34. List of Caldolor drug patents

35. List of Cerdelga drug patents

36. List of Children's Allegra Allergy drug patents

37. List of Combivent Respimat drug patents

38. List of Cometriq drug patents

39. List of Consensi drug patents

40. List of Contrave drug patents

41. List of Copiktra drug patents

42. List of Cotellic drug patents

43. List of Cubicin drug patents

44. List of Cycloset drug patents

45. List of Dexilant drug patents

46. List of Dextenza drug patents

47. List of Dsuvia drug patents

48. List of Edarbyclor drug patents

49. List of Ella drug patents

50. List of Entereg drug patents

51. List of Epclusa drug patents

52. List of Erleada drug patents

53. List of Esbriet drug patents

54. List of Eucrisa drug patents

55. List of Evomela drug patents

56. List of Exem Foam Kit drug patents

57. List of Fabior drug patents

58. List of Fanapt drug patents

59. List of Farxiga drug patents

60. List of Flolipid drug patents

61. List of Fosrenol drug patents

62. List of Fyarro drug patents

63. List of Gemtesa drug patents

64. List of Genosyl drug patents

65. List of Genvoya drug patents

66. List of Gilotrif drug patents

67. List of Gimoti drug patents

68. List of Gocovri drug patents

69. List of Harvoni drug patents

70. List of Ibsrela drug patents

71. List of Idhifa drug patents

72. List of Ilevro drug patents

73. List of Implanon drug patents

74. List of Impoyz drug patents

75. List of Incruse Ellipta drug patents

76. List of Inlyta drug patents

77. List of Inqovi drug patents

78. List of Intrarosa drug patents

Strength	Dosage	Availability
EQ 400MG BASE	TABLET;ORAL	Prescription
EQ 600MG BASE	TABLET;ORAL	Prescription

Strength	Dosage	Availability
158MG	CAPSULE;ORAL	Prescription
198MG	CAPSULE;ORAL	Prescription
237MG	CAPSULE;ORAL	Prescription

Strength	Dosage	Availability
2.5MG;1GM	TABLET;ORAL	Prescription
2.5MG;500MG	TABLET;ORAL	Prescription
2.5MG;850MG	TABLET;ORAL	Prescription

Strength	Dosage	Availability
2.5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription

Strength	Dosage	Availability
10MG	FILM;SUBLINGUAL	Prescription
15MG	FILM;SUBLINGUAL	Prescription
20MG	FILM;SUBLINGUAL	Prescription
25MG	FILM;SUBLINGUAL	Prescription
30MG	FILM;SUBLINGUAL	Prescription

Strength	Dosage	Availability
100MG	CAPSULE;ORAL	Prescription
150MG	CAPSULE;ORAL	Prescription
200MG	CAPSULE;ORAL	Prescription

Strength	Dosage	Availability
EQ 0.25MG BASE	TABLET;ORAL	Prescription
EQ 1MG BASE	TABLET;ORAL	Prescription
EQ 2MG BASE	TABLET;ORAL	Prescription

Strength	Dosage	Availability
EQ 0.5MG	TABLET;ORAL	Prescription
EQ 1MG	TABLET;ORAL	Discontinued
EQ 2MG	TABLET;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0375 mg/day 0.05 mg/day 0.075 mg/day 0.1 mg/day	18 Aug, 2014	1	15 Aug, 2018	04 Jul, 2030	Deferred
0.025 mg/day	08 May, 2015	1	15 Aug, 2018	04 Jul, 2030	Deferred

Strength	Dosage	Availability
0.025MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
0.0375MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
0.05MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
0.075MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
0.1MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription